Portugal introduces a scheme that subsidises 15% of obesity medication costs for patients who are enrolled in a specific hospital-based monitoring and care model. Access is not open to the general public based on need alone; reimbursement is tied to participation in multidisciplinary obesity management groups linked to local health units.
Under the programme, prescriptions must come from a defined set of specialists—endocrinologists, internal medicine doctors, or paediatricians—who are part of the relevant hospital core team. Patients must follow an integrated care pathway that combines medication with broader management, including support for physical activity and nutrition, and psychological accompaniment. Outlets also note that eligibility depends on maintaining an active medical record within the national obesity prevention and control framework and the specific integrated care pathway established by the health authorities.
The reporting broadly agrees on the 15% subsidy level and the restriction to patients under hospital monitoring. The main difference is emphasis: one outlet highlights the full set of programme requirements and care components, while the other focuses more concisely on the subsidy and specialist prescribing conditions.
